{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "e931e4f2",
   "metadata": {},
   "source": [
    "## Loads"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "e3c8c716",
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "import os\n",
    "script_dir = os.getcwd()\n",
    "root_dir = os.path.join(os.path.dirname(os.path.abspath(script_dir)))\n",
    "sys.path.append(root_dir)\n",
    "os.chdir(root_dir)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "852fa8e0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/home/helenajun/rag-llm-cancer-paper'"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "os.getcwd()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "242fdcda",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'2025-09-04'"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# !pip install rank_bm25\n",
    "import json\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "from utils.io import load_object, save_object\n",
    "from utils.evaluation import calc_eval_metrics, get_avg_eval_runs, plot_radar_chart\n",
    "from utils.check_db_version import get_local_version\n",
    "import colorcet as cc\n",
    "import ast\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "import math\n",
    "\n",
    "_VERSION=get_local_version()\n",
    "_VERSION"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "12417a5a",
   "metadata": {},
   "source": [
    "## Real-world query characteristics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "f3303cbf",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "prompt",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "cancer_category",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "cancer_type",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "biomarker",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "dataset",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "922b8bad-93bd-4dfc-ab07-7127082ce015",
       "rows": [
        [
         "0",
         "what is the first-line treatment of metastatic urothelial carcinoma with fgfr3 s249c mutation?",
         "GU",
         "['urothelial carcinoma', 'metastatic']",
         "['fgfr3']",
         "test"
        ],
        [
         "1",
         "are parp inhibitors used for patients with leiomyosarcoma who have mutations in dna damage repair genes?",
         "Sarcoma",
         "['leiomyosarcoma']",
         "['dna', 'parp']",
         "test"
        ],
        [
         "2",
         "are alk inhibitors approved for use in tfcp2 fusion positive rhabdomyosarcoma?",
         "Sarcoma",
         "['rhabdomyosarcoma']",
         "['alk', 'tfcp2']",
         "validation"
        ],
        [
         "3",
         "for a patient with cancer metastatic prostate cancer, advanced stage (most often stage iv, but some stage iii or earlier potentially) and with brca2 mutation, what drugs approved?",
         "GU",
         "['prostate cancer', 'cancer']",
         "['brca2']",
         "test"
        ],
        [
         "4",
         "for a patient with her2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?",
         "Breast",
         "['breast cancer', 'disease']",
         "['her2']",
         "test"
        ]
       ],
       "shape": {
        "columns": 5,
        "rows": 5
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>prompt</th>\n",
       "      <th>cancer_category</th>\n",
       "      <th>cancer_type</th>\n",
       "      <th>biomarker</th>\n",
       "      <th>dataset</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>what is the first-line treatment of metastatic...</td>\n",
       "      <td>GU</td>\n",
       "      <td>[urothelial carcinoma, metastatic]</td>\n",
       "      <td>['fgfr3']</td>\n",
       "      <td>test</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>are parp inhibitors used for patients with lei...</td>\n",
       "      <td>Sarcoma</td>\n",
       "      <td>[leiomyosarcoma]</td>\n",
       "      <td>['dna', 'parp']</td>\n",
       "      <td>test</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>are alk inhibitors approved for use in tfcp2 f...</td>\n",
       "      <td>Sarcoma</td>\n",
       "      <td>[rhabdomyosarcoma]</td>\n",
       "      <td>['alk', 'tfcp2']</td>\n",
       "      <td>validation</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>for a patient with cancer metastatic prostate ...</td>\n",
       "      <td>GU</td>\n",
       "      <td>[prostate cancer, cancer]</td>\n",
       "      <td>['brca2']</td>\n",
       "      <td>test</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>for a patient with her2+ breast cancer after n...</td>\n",
       "      <td>Breast</td>\n",
       "      <td>[breast cancer, disease]</td>\n",
       "      <td>['her2']</td>\n",
       "      <td>test</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                              prompt cancer_category  \\\n",
       "0  what is the first-line treatment of metastatic...              GU   \n",
       "1  are parp inhibitors used for patients with lei...         Sarcoma   \n",
       "2  are alk inhibitors approved for use in tfcp2 f...         Sarcoma   \n",
       "3  for a patient with cancer metastatic prostate ...              GU   \n",
       "4  for a patient with her2+ breast cancer after n...          Breast   \n",
       "\n",
       "                          cancer_type         biomarker     dataset  \n",
       "0  [urothelial carcinoma, metastatic]         ['fgfr3']        test  \n",
       "1                    [leiomyosarcoma]   ['dna', 'parp']        test  \n",
       "2                  [rhabdomyosarcoma]  ['alk', 'tfcp2']  validation  \n",
       "3           [prostate cancer, cancer]         ['brca2']        test  \n",
       "4            [breast cancer, disease]          ['her2']        test  "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "real_world_query=pd.read_csv(\"data/real_world_db/real_world_db_split__v1.csv\", index_col=0)\n",
    "real_world_query['cancer_type']=real_world_query['cancer_type'].apply(ast.literal_eval)\n",
    "real_world_query.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b2fda3f4",
   "metadata": {},
   "source": [
    "### Standardize cancer names"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "2a2cd39b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index([                                                                                                  [],\n",
       "                                                                                          ['breast cancer'],\n",
       "                                                                                         ['bladder cancer'],\n",
       "                                                                                          ['neuroblastoma'],\n",
       "                                                                                        ['prostate cancer'],\n",
       "                                                                                      ['colorectal cancer'],\n",
       "                                                                     ['urothelial carcinoma', 'metastatic'],\n",
       "                                                                                     ['cholangiocarcinoma'],\n",
       "                                                                         ['muscle-invasive bladder cancer'],\n",
       "                                                                                    ['lung adenocarcinoma'],\n",
       "                                                                                           ['osteosarcoma'],\n",
       "                                                                                ['thyroid cancer', 'tumor'],\n",
       "                                                                                   ['urothelial carcinoma'],\n",
       "                                                                            ['tumor', 'cholangiocarcinoma'],\n",
       "                                                                                    ['follicular lymphoma'],\n",
       "                                                                                ['high-risk neuroblastoma'],\n",
       "                                                                                                 ['cancer'],\n",
       "                                                                                         ['hepatoblastoma'],\n",
       "                                                                          ['prostate cancer', 'castration'],\n",
       "                                                                                       ['rhabdomyosarcoma'],\n",
       "                                                                                  ['nut midline carcinoma'],\n",
       "                                                                                  ['colo-rectal carcinoma'],\n",
       "                                                                                  ['lobular breast cancer'],\n",
       "                                                                            ['breast cancer', 'lumpectomy'],\n",
       "                                                                                 ['gastric adenocarcinoma'],\n",
       "                                                                   ['high grade serious ovarian carcinoma'],\n",
       "                                                                         ['ascending colon adenocarcinoma'],\n",
       "                                                                                   ['colon adenocarcinoma'],\n",
       "                                                                               ['tumor', 'prostate cancer'],\n",
       "                                                                              ['prostate cancer', 'cancer'],\n",
       "                                                                      ['tumor', 'primary', 'kidney cancer'],\n",
       "                                                                          ['testicular cancer', 'platinum'],\n",
       "                                                                                   ['biliary tract cancer'],\n",
       "                                                                     ['tumor', 'pancreatic adenocarcinoma'],\n",
       "                                                                                      ['pancreatic cancer'],\n",
       "                                                    ['gastroesophageal junction adenocarcinoma', 'gastric'],\n",
       "                                                                                     ['lymphoid neoplasms'],\n",
       "                                                               ['gastroesophageal junction adenocarcinoma'],\n",
       "                                                                                         ['desmoid tumors'],\n",
       "                                                       ['locally advanced', 'bladder cancer', 'metastatic'],\n",
       "                                                                                 ['high grade wilms tumor'],\n",
       "       ['peripheral nerve sheath tumor', 'plexiform neurofibroma', 'neurofibromatosis type 1', 'malignant'],\n",
       "                                                    ['renal mass', 'clear-cell renal cell carcinoma tumor'],\n",
       "                                                                        ['intrahepatic cholangiocarcinoma'],\n",
       "                                                               ['oligodendroglioma', 'grade 2 astrocytoma'],\n",
       "                                                                                  ['tumor', 'osteosarcoma'],\n",
       "                                                                     ['non-small cell lung adenocarcinoma'],\n",
       "                                                                                 ['tumor', 'breast cancer'],\n",
       "                                                                             ['non-small cell lung cancer'],\n",
       "                                                                                 ['melanoma', 'metastatic'],\n",
       "                                                                        ['clear-cell renal cell carcinoma'],\n",
       "                                                                             ['ewing sarcoma', 'localized'],\n",
       "                                                                                 ['acute myeloid leukemia'],\n",
       "                                                                                        ['medulloblastoma'],\n",
       "                                                                     ['tumor', 'anaplastic thyroid cancer'],\n",
       "                                                                       ['pancreatic ductal adenocarcinoma'],\n",
       "                                                                      ['tumor', 'medullary thyroid cancer'],\n",
       "                                                                                         ['leiomyosarcoma'],\n",
       "                                                                               ['breast cancer', 'disease'],\n",
       "                                                                             ['non small cell lung cancer'],\n",
       "                                                                                  ['endometrial carcinoma'],\n",
       "                                                                         ['breast carcinoma', 'metastatic'],\n",
       "                                                                                            ['lung cancer'],\n",
       "                                                                               ['clear-cell kidney cancer']],\n",
       "      dtype='object', name='cancer_type')"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "real_world_query['cancer_type'].value_counts().keys()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "a48defdf",
   "metadata": {},
   "outputs": [],
   "source": [
    "cancer_mapping={\n",
    "    'breast cancer':['breast cancer','lobular breast cancer','breast carcinoma'],\n",
    "    'bladder cancer':['bladder cancer','urothelial carcinoma','muscle-invasive bladder cancer'],\n",
    "    'neuroblastoma':['neuroblastoma','high-risk neuroblastoma'],\n",
    "    'prostate cancer':['prostate cancer'],\n",
    "    'colorectal cancer':['colorectal cancer','colo-rectal carcinoma','ascending colon adenocarcinoma','colon adenocarcinoma'],\n",
    "    'cholangiocarcinoma':['cholangiocarcinoma','intrahepatic cholangiocarcinoma'],\n",
    "    'lung cancer':['lung cancer','lung adenocarcinoma','non-small cell lung adenocarcinoma','non-small cell lung cancer','non small cell lung cancer'],\n",
    "    'osteosarcoma':['osteosarcoma'],\n",
    "    'thyroid cancer':['thyroid cancer','anaplastic thyroid cancer','medullary thyroid cancer'],\n",
    "    'follicular lymphoma':['follicular lymphoma'],\n",
    "    'hepatoblastoma':['hepatoblastoma'],\n",
    "    'rhabdomyosarcoma':['rhabdomyosarcoma'],\n",
    "    'nut midline carcinoma':['nut midline carcinoma'],\n",
    "    'stomach cancer':['gastric adenocarcinoma','gastroesophageal junction adenocarcinoma'],\n",
    "    'ovarian cancer':['high grade serious ovarian carcinoma'],\n",
    "    'kidney cancer':['kidney cancer','clear-cell renal cell carcinoma tumor','clear-cell renal cell carcinoma','clear-cell kidney cancer'],\n",
    "    'testicular cancer':['testicular cancer'],\n",
    "    'biliary tract cancer':['biliary tract cancer'],\n",
    "    'pancreatic cancer':['pancreatic cancer','pancreatic adenocarcinoma','pancreatic ductal adenocarcinoma'],\n",
    "    'lymphoid neoplasms':['lymphoid neoplasms'],\n",
    "    'desmoid tumors':['desmoid tumors'],\n",
    "    'wilms tumor':['wilms tumor','high grade wilms tumor'],\n",
    "    'peripheral nerve sheath tumor':['peripheral nerve sheath tumor'],\n",
    "    'oligodendroglioma':['oligodendroglioma'],\n",
    "    'melanoma':['melanoma'],\n",
    "    'ewing sarcoma':['ewing sarcoma'],\n",
    "    'acute myeloid leukemia':['acute myeloid leukemia'],\n",
    "    'medulloblastoma':['medulloblastoma'],\n",
    "    'leiomyosarcoma':['leiomyosarcoma'],\n",
    "    'endometrial cancer':['endometrial carcinoma'],\n",
    "    'b-cell acute lymphoblastic leukemia':['b-cell acute lymphoblastic leukemia','b-all'],\n",
    "    'midline glioma':['midline glioma'],\n",
    "    'anaplastic large cell lymphoma':['anaplastic large cell lymphoma']\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "98246334",
   "metadata": {},
   "outputs": [],
   "source": [
    "real_world_query['standardized_cancer_type']=None\n",
    "for k, v in cancer_mapping.items():\n",
    "    for idx, c in enumerate(real_world_query['cancer_type']):\n",
    "        if set(c).intersection(set(v)):\n",
    "            real_world_query.at[idx, 'standardized_cancer_type']=k"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "de32d232",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "for patients with advanced cancer and with ntrk fusions, regardless of cancer types, are there drugs approved?\n",
      "for patients with advanced cancer and with high tmb, regardless of cancer types, are there drugs approved?\n",
      "is there an optimal drug combination to minimize the risk of post hsct relapse in a 2 year old with kmt2a rearranged aml?\n",
      "i have a patient with stage iii nsclc with an l858r mutation who was treated with chemoradiation and had a partial radiographic response. what are adjuvant therapy options? if there are multiple, what is the preferred option?\n",
      "my metastatic cutaneous melanoma patient has high tmb and a braf mutation. what should i do?\n",
      "i have a patient with radioactive iodine referactory thyroid cancer. what is the first line option?\n",
      "for a patient with relapsed b-all that expresses cd22, what antibody-drug conjugates may be used?\n",
      "for a patient with relapsed b-all that expresses cd19, what targeted treatment options exist?\n",
      "what targeted treatment options exist for patients with aml and flt3-itd?\n",
      "are there any targeted treatments for h3k27m diffuse midline glioma?\n",
      "i have a patient with newly diagnosed aml that has mutations in tp53 and idh1. are there any therapies that i should be thinking about in this setting?\n",
      "my patient whas relapsed aml that includes an idh2 mutation. what is the correct treatment strategy based on this information?\n",
      "for a cll patient with del 17p are there targeted therapies i could consider?\n",
      "for a patient with a bcor::ccnb3 fusion (bcs), is there a targeted therapy?\n",
      "i have a patient with metastatic descending colon adenocarcinoma, that is kras and braf wt, what first line targeted therapy therapy options are there in addition to folfox or folfiri\n",
      "i have a patient with metastatic descending colon adenocarcinoma, that is kras wt and braf mutant, what targeted therapy therapy options are there in the first line setting\n",
      "i have a patient with unresectable fgfr fusion cholangiocarcinoma, what targeted treatment options are available in the first line\n",
      "what is a targeted therapy that can be used for the treatment of relapsed/refractory systemic anaplastic large cell lymphoma that is alk positive?\n"
     ]
    }
   ],
   "source": [
    "for idx, row in real_world_query[real_world_query['standardized_cancer_type'].isna()].iterrows():\n",
    "    print(row['prompt'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dd177e2c",
   "metadata": {},
   "outputs": [],
   "source": [
    "ner_missed_cancer=['unspecified',\n",
    " 'unspecified',\n",
    " 'acute myeloid leukemia',\n",
    " 'lung cancer',\n",
    " 'melanoma',\n",
    " 'thyroid cancer',\n",
    " 'b-cell acute lymphoblastic leukemia',\n",
    " 'b-cell acute lymphoblastic leukemia',\n",
    " 'acute myeloid leukemia',\n",
    " 'midline glioma',\n",
    " 'acute myeloid leukemia',\n",
    " 'acute myeloid leukemia',\n",
    " 'chronic lymphocytic leukemia',\n",
    " 'unspecified',\n",
    " 'colorectal cancer',\n",
    " 'colorectal cancer',\n",
    " 'cholangiocarcinoma',\n",
    " 'anaplastic large cell lymphoma'\n",
    " ]\n",
    "\n",
    "len(ner_missed_cancer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "69b46004",
   "metadata": {},
   "outputs": [],
   "source": [
    "ner_missed_idx=real_world_query[real_world_query['standardized_cancer_type'].isna()].index\n",
    "real_world_query.loc[ner_missed_idx, \"standardized_cancer_type\"]=ner_missed_cancer"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8c5451e2",
   "metadata": {},
   "source": [
    "### Number of biomarkers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9763f249",
   "metadata": {},
   "outputs": [],
   "source": [
    "unique_biomarkers=real_world_query['biomarker'].drop_duplicates()\n",
    "unique_biomarkers_ls=[]\n",
    "for biomarker in unique_biomarkers:\n",
    "    biomarkers=ast.literal_eval(biomarker)\n",
    "    for b in biomarkers:\n",
    "        if b not in unique_biomarkers_ls:\n",
    "            unique_biomarkers_ls.append(b)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5d451241",
   "metadata": {},
   "outputs": [],
   "source": [
    "exclude=['ihc 1','nsclc','aml','fda','parp','dna','hormone','bcs']\n",
    "syns={\n",
    "    'er':['estrogen receptor'],\n",
    "    'hr':['hormone receptor'],\n",
    "    'braf v600e':['brafv600e'],\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9f8c707e",
   "metadata": {},
   "outputs": [],
   "source": [
    "biomarkers={k if b in v else b for k, v in syns.items() for b in unique_biomarkers_ls}\n",
    "for i in exclude:\n",
    "    biomarkers.remove(i)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4f2d5539",
   "metadata": {},
   "source": [
    "### Visualize cancer categories and types"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "823d49ef",
   "metadata": {},
   "source": [
    "Cancer category: cancer type grouped by its organ or system"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 166,
   "id": "1bb9f955",
   "metadata": {},
   "outputs": [],
   "source": [
    "counts=real_world_query['cancer_category'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 168,
   "id": "68f0ccd0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 500x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "cols=sns.color_palette(\"tab20\")\n",
    "def autopct_func(pct):\n",
    "    return f\"{pct:.0f}%\" if pct > 2 else \"\"  # only show if pct >= 3\n",
    "\n",
    "fig, ax = plt.subplots(figsize=(5, 5))\n",
    "wedges, _, autotexts = ax.pie(\n",
    "    counts,\n",
    "    autopct=autopct_func,\n",
    "    startangle=90,\n",
    "    counterclock=False,\n",
    "    colors=cols,\n",
    "    wedgeprops=dict(edgecolor='white')\n",
    ")\n",
    "for t in autotexts: \n",
    "    t.set_fontsize(10)\n",
    "ax.legend(\n",
    "    wedges, \n",
    "    counts.index, \n",
    "    # title='Cancer Type', \n",
    "    loc='center left', \n",
    "    bbox_to_anchor=(1,0.5),\n",
    "    frameon=False\n",
    "    )\n",
    "plt.title(\"Cancer Type Distribution\\n(grouped by organ/system)\")\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c3444007",
   "metadata": {},
   "source": [
    "Cancer type: specific cancer types"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 148,
   "id": "83ca7cb1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "35"
      ]
     },
     "execution_count": 148,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "counts=real_world_query['standardized_cancer_type'].value_counts()\n",
    "n_unique=counts.keys().nunique()\n",
    "n_unique"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1cfe8faa",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 600x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "counts[::-1].plot(\n",
    "    kind=\"barh\", \n",
    "    color=\"darkgreen\",\n",
    "    figsize=(6, 6)\n",
    "    )\n",
    "plt.xlabel(\"Count\")\n",
    "plt.ylabel(\"Cancer Type\")\n",
    "plt.title(\"Cancer Type Distribution\")\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 181,
   "id": "4ed9434b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "dataset",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "count",
         "rawType": "int64",
         "type": "integer"
        }
       ],
       "ref": "ed693fb0-e791-405d-b7f0-b8ca3c2ad3c4",
       "rows": [
        [
         "test",
         "90"
        ],
        [
         "validation",
         "12"
        ]
       ],
       "shape": {
        "columns": 1,
        "rows": 2
       }
      },
      "text/plain": [
       "dataset\n",
       "test          90\n",
       "validation    12\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 181,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "real_world_query['dataset'].value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e426bd2a",
   "metadata": {},
   "source": [
    "## Real-world query validation"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6ed5e79b",
   "metadata": {},
   "source": [
    "### Define metrics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "29d064d9",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Define evaluation keys\n",
    "METRICS = {\n",
    "    \"exact\": \"avg_exact_match_acc\",\n",
    "    \"partial\": \"avg_partial_match_acc\",\n",
    "    \"precision\": \"avg_precision\",\n",
    "    \"recall\": \"avg_recall\",\n",
    "    \"f1\": \"avg_f1\",\n",
    "    \"specificity\": \"avg_specificity\"\n",
    "}"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2de622e4",
   "metadata": {},
   "source": [
    "### Define evaluator"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "47e4b063",
   "metadata": {},
   "outputs": [],
   "source": [
    "class Evaluator:\n",
    "    def __init__(self, pipelines, strategies, metrics, query, true_dict, mode_paths, num_iter=1, subset_idx=None):\n",
    "        \"\"\"\n",
    "        pipelines: list of pipelines ('RAG' for rag-llm or 'LLM' for llm-only)\n",
    "        strategies: str (e.g., \"0\" for basic prompt or \"5\" for scope-defined prompt)\n",
    "        mode_paths: dict of {mode_name: base_filepath}\n",
    "        Example: {\n",
    "            \"dense\": _DENSE_FILEPATH,\n",
    "            \"hybrid\": _HYBRID_FILEPATH\n",
    "        }\n",
    "        \"\"\"\n",
    "        if isinstance(pipelines, str):\n",
    "            pipelines = [pipelines]\n",
    "            \n",
    "        self.pipelines = pipelines\n",
    "        self.strategies = strategies\n",
    "        self.metrics = metrics\n",
    "        self.true_dict = true_dict\n",
    "        self.mode_paths = mode_paths\n",
    "        self.num_iter = num_iter\n",
    "        self.subset_idx = subset_idx\n",
    "        \n",
    "        # Subset queries if provided\n",
    "        if self.subset_idx is not None:\n",
    "            self.query = query.iloc[self.subset_idx]\n",
    "        else:\n",
    "            self.query = query\n",
    "        \n",
    "        # Initialize results for all pipelines and modes\n",
    "        self.results = { \n",
    "            pipeline: {\n",
    "                mode: {m: {s: [] for s in strategies} for m in metrics}\n",
    "                for mode in mode_paths\n",
    "                }\n",
    "            for pipeline in self.pipelines\n",
    "        }\n",
    "        \n",
    "        self.evals = {\n",
    "            pipeline: {\n",
    "                mode: {s: [] for s in strategies}\n",
    "                for mode in mode_paths\n",
    "                }\n",
    "            for pipeline in self.pipelines\n",
    "        }\n",
    "        \n",
    "        self.llm_input = {\n",
    "            pipeline: {\n",
    "                mode: {s: [] for s in strategies}\n",
    "                for mode in mode_paths\n",
    "                }\n",
    "            for pipeline in self.pipelines\n",
    "        }\n",
    "        \n",
    "        self.llm_output = {\n",
    "            pipeline: {\n",
    "                mode: {s: [] for s in strategies}\n",
    "                for mode in mode_paths\n",
    "                }\n",
    "            for pipeline in self.pipelines\n",
    "        }\n",
    "        \n",
    "        self.retrieval = {\n",
    "            pipeline: {\n",
    "                mode: {s: [] for s in strategies}\n",
    "                for mode in mode_paths\n",
    "                }\n",
    "            for pipeline in self.pipelines\n",
    "        }\n",
    "\n",
    "    def evaluate_strategy(self, pipeline, mode):\n",
    "        base_path = self.mode_paths[mode]\n",
    "        for s in self.strategies:\n",
    "            filepath = os.path.join(base_path, f\"{pipeline}stra{s}n{self.num_iter}temp0.0_res_dict.pkl\")\n",
    "            obj = load_object(filepath)\n",
    "            \n",
    "            for i in range(self.num_iter):\n",
    "                try:\n",
    "                    input_prompt = obj[\"input prompt\"][i]\n",
    "                    full_output = obj[\"full output\"][i]\n",
    "                    retrieval_output = obj[\"retrieval\"][i]\n",
    "                    \n",
    "                    if self.subset_idx is not None:\n",
    "                        input_prompt_subset = [input_prompt[j] for j in self.subset_idx]\n",
    "                        full_output_subset = [full_output[j] for j in self.subset_idx]\n",
    "                        retrieval_subset = [retrieval_output[j] for j in self.subset_idx]\n",
    "                    else:\n",
    "                        input_prompt_subset = input_prompt\n",
    "                        full_output_subset = full_output\n",
    "                        retrieval_subset = retrieval_output\n",
    "                        \n",
    "                    eval_dict = calc_eval_metrics(\n",
    "                        full_output_subset,\n",
    "                        self.query[\"prompt\"].tolist(),\n",
    "                        self.true_dict\n",
    "                    )\n",
    "                    self.evals[pipeline][mode][s].append(eval_dict)\n",
    "                    self.llm_input[pipeline][mode][s].append(input_prompt_subset)\n",
    "                    self.llm_output[pipeline][mode][s].append(full_output_subset)\n",
    "                    self.retrieval[pipeline][mode][s].append(retrieval_subset)\n",
    "                    for name, key in self.metrics.items():\n",
    "                        self.results[pipeline][mode][name][s].append(eval_dict[key])\n",
    "                except Exception:\n",
    "                    continue\n",
    "\n",
    "    def run(self):\n",
    "        for pipeline in self.pipelines:\n",
    "            for mode in self.mode_paths:\n",
    "                self.evaluate_strategy(pipeline, mode)\n",
    "\n",
    "    def average(self):\n",
    "        average = {}\n",
    "        for pipeline in self.pipelines:\n",
    "            average[pipeline] = {}\n",
    "            for mode in self.mode_paths:\n",
    "                average[pipeline][mode] = {\n",
    "                    m: {s: np.mean(vals) if vals else None for s, vals in strat.items()}\n",
    "                    for m, strat in self.results[pipeline][mode].items()\n",
    "                }\n",
    "        return average\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1374de34",
   "metadata": {},
   "source": [
    "### Define compare modes functions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "c1117d14",
   "metadata": {},
   "outputs": [],
   "source": [
    "def compare_mode_A_vs_B(A_failed, B_failed):\n",
    "    both_success, both_failed, A_failed_B_success, A_success_B_failed = 0, 0, 0, 0\n",
    "    \n",
    "    for A_fail, B_fail in zip(A_failed, B_failed):\n",
    "        if A_fail and B_fail:\n",
    "            both_failed += 1\n",
    "        elif A_fail and not B_fail:\n",
    "            A_failed_B_success += 1\n",
    "        elif not A_fail and B_fail:\n",
    "            A_success_B_failed += 1\n",
    "        else:\n",
    "            both_success += 1\n",
    "    return [both_success, A_success_B_failed,\n",
    "            A_failed_B_success, both_failed]\n",
    "\n",
    "def compare_mode_A_vs_B_idx(A_failed, B_failed):\n",
    "    both_success, both_failed, A_failed_B_success, A_success_B_failed = [], [], [], []\n",
    "    for i, (A_fail, B_fail) in enumerate(zip(A_failed, B_failed)):\n",
    "        if A_fail and B_fail:\n",
    "            both_failed.append(i)\n",
    "        elif A_fail and not B_fail:\n",
    "            A_failed_B_success.append(i)\n",
    "        elif not A_fail and B_fail:\n",
    "            A_success_B_failed.append(i)\n",
    "        else:\n",
    "            both_success.append(i)\n",
    "    return {\n",
    "        \"both_success\": both_success,\n",
    "        \"both_failed\": both_failed,\n",
    "        \"A_failed_B_success\": A_failed_B_success,\n",
    "        \"A_success_B_failed\": A_success_B_failed\n",
    "    }"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "78973ab1",
   "metadata": {},
   "source": [
    "### Dense vs. Hybrid"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "dee22bf5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'dense': {'exact': {'5': 0.838095238095238},\n",
       "  'partial': {'5': 0.980952380952381},\n",
       "  'precision': {'5': 0.9333333333333332},\n",
       "  'recall': {'5': 0.8106060606060606},\n",
       "  'f1': {'5': 0.8454545454545453},\n",
       "  'specificity': {'5': 0.9994834710743803}},\n",
       " 'hybrid': {'exact': {'5': 0.8095238095238095},\n",
       "  'partial': {'5': 0.9523809523809523},\n",
       "  'precision': {'5': 0.8863636363636364},\n",
       "  'recall': {'5': 0.7742424242424242},\n",
       "  'f1': {'5': 0.8060606060606063},\n",
       "  'specificity': {'5': 0.9994834710743803}}}"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "num_iter = 5\n",
    "strategies = [\"5\"]\n",
    "_PIPELINE='RAG'\n",
    "_DENSE_FILEPATH = 'output/RAG_res_gpt4o_default/structured_realworld_val_v2_dense'\n",
    "_HYBRID_FILEPATH = 'output/RAG_res_gpt4o_default/structured_realworld_val_v2_hybrid'\n",
    "_QUERY_VAL = pd.read_csv(f\"data/real_world_db/real_world_validation__v2.csv\", index_col=0)\n",
    "_QUERY_TRUE = load_object(\"data/real_world_db/real_world_query_therapy_pair_dict.pkl\")\n",
    "\n",
    "mode_paths = {\n",
    "    \"dense\": _DENSE_FILEPATH,\n",
    "    \"hybrid\": _HYBRID_FILEPATH\n",
    "}\n",
    "\n",
    "evaluator_val_queries = Evaluator(\n",
    "    pipelines=_PIPELINE,\n",
    "    strategies=strategies,\n",
    "    metrics=METRICS,\n",
    "    query=_QUERY_VAL,\n",
    "    true_dict=_QUERY_TRUE,\n",
    "    mode_paths=mode_paths,\n",
    "    num_iter=num_iter\n",
    ")\n",
    "\n",
    "evaluator_val_queries.run()\n",
    "average = evaluator_val_queries.average()\n",
    "\n",
    "val_queries_results=evaluator_val_queries.results['RAG']\n",
    "val_queries_average=average['RAG']\n",
    "val_queries_average"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "55e5183d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 500x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "cols = sns.color_palette(cc.glasbey)\n",
    "\n",
    "eval_metrics_text = dict(zip(METRICS.keys(),\n",
    "                             ['Exact accuracy','Partial accuracy','Precision','Recall','F1 Score','Specificity']))\n",
    "\n",
    "plot_results = {\n",
    "    'RAG + hybrid': {k: v['5']*100 for k, v in val_queries_average['hybrid'].items()},\n",
    "    'RAG + dense-only': {k: v['5']*100 for k, v in val_queries_average['dense'].items()},\n",
    "}\n",
    "\n",
    "plot_radar_chart(\n",
    "    eval_results=plot_results, \n",
    "    metrics=eval_metrics_text.keys(), \n",
    "    metric_labels=eval_metrics_text,\n",
    "    title=None,\n",
    "    colors=[cols[6],cols[0]]\n",
    "    )"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4bbfc7b6",
   "metadata": {},
   "source": [
    "Analyze failures:\n",
    "- Are errors due to retrieval (recall of relevant contexts), reasoning (does the LLM use the retrieved info correctly?), or both?\n",
    "\n",
    "Categorize errors:\n",
    "- Retrieval failure (missing context)\n",
    "- Misinterpretation (LLM misuses retrieved evidence)\n",
    "- Hallucination/misattribution (LLM generates unsupported facts)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "80883f1c",
   "metadata": {},
   "source": [
    "#### Partial match error analysis results\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "610a133d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'both_success': [0, 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20], 'both_failed': [], 'A_failed_B_success': [], 'A_success_B_failed': [7]}, {'both_success': [0, 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20], 'both_failed': [], 'A_failed_B_success': [], 'A_success_B_failed': [7]}, {'both_success': [0, 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20], 'both_failed': [], 'A_failed_B_success': [], 'A_success_B_failed': [7]}, {'both_success': [0, 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20], 'both_failed': [7], 'A_failed_B_success': [], 'A_success_B_failed': []}, {'both_success': [0, 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20], 'both_failed': [7], 'A_failed_B_success': [], 'A_success_B_failed': []}]\n"
     ]
    }
   ],
   "source": [
    "all_results_idx = []\n",
    "for i in range(5): \n",
    "    dense_partial_failed = ~np.array(evaluator_val_queries.evals['RAG']['dense']['5'][i]['partial_match_acc'])\n",
    "    hybrid_partial_failed = ~np.array(evaluator_val_queries.evals['RAG']['hybrid']['5'][i]['partial_match_acc'])\n",
    "    all_results_idx.append(compare_mode_A_vs_B_idx(dense_partial_failed, hybrid_partial_failed))\n",
    "print(all_results_idx)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "6c232d7d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "count",
         "rawType": "int64",
         "type": "integer"
        }
       ],
       "ref": "cd134e8d-c016-4821-86d6-18d1a73d0095",
       "rows": [
        [
         "7",
         "2"
        ]
       ],
       "shape": {
        "columns": 1,
        "rows": 1
       }
      },
      "text/plain": [
       "7    2\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_runs=[all_results_idx[i]['both_failed'] for i in range(5)]\n",
    "pd.Series([x for run in all_runs for x in run]).value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "b7326621",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "count",
         "rawType": "int64",
         "type": "integer"
        }
       ],
       "ref": "f48bb3c3-491d-4ca2-9b0a-8325ebfc06fb",
       "rows": [],
       "shape": {
        "columns": 1,
        "rows": 0
       }
      },
      "text/plain": [
       "Series([], Name: count, dtype: int64)"
      ]
     },
     "execution_count": 59,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_runs=[all_results_idx[i]['A_failed_B_success'] for i in range(5)]\n",
    "pd.Series([x for run in all_runs for x in run]).value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "fa10cc59",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "count",
         "rawType": "int64",
         "type": "integer"
        }
       ],
       "ref": "413dc469-d2d5-4c26-b1a6-bc1b86705319",
       "rows": [
        [
         "7",
         "3"
        ]
       ],
       "shape": {
        "columns": 1,
        "rows": 1
       }
      },
      "text/plain": [
       "7    3\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_runs=[all_results_idx[i]['A_success_B_failed'] for i in range(5)]\n",
    "pd.Series([x for run in all_runs for x in run]).value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "7eb8b761",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "============= query =============\n",
      "(0, 7): what fda-approved therapies exist for a stage iv pancreatic ductal adenocarcinoma patient with a ntrk mutation\n",
      "============= ground-truth =============\n",
      "{frozenset({'larotrectinib'}), frozenset({'entrectinib'}), frozenset({'repotrectinib'})}\n",
      "============= dense =============\n",
      "{frozenset({'larotrectinib'}), frozenset({'entrectinib'}), frozenset({'repotrectinib'})}\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Pancreatic Ductal Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Stage IV\",\n",
      "        \"Drug Name\": \"Repotrectinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory alternative therapy\",\n",
      "        \"Genomic Features\": \"NTRK gene fusion\",\n",
      "        \"FDA-approval status\": \"Approved under accelerated approval based on overall response rate and duration of response\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Pancreatic Ductal Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Stage IV\",\n",
      "        \"Drug Name\": \"Entrectinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory alternative therapy\",\n",
      "        \"Genomic Features\": \"NTRK gene fusion\",\n",
      "        \"FDA-approval status\": \"Approved under accelerated approval based on tumor response rate and durability of response\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Pancreatic Ductal Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Stage IV\",\n",
      "        \"Drug Name\": \"Larotrectinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or that have progressed following treatment\",\n",
      "        \"Genomic Features\": \"NTRK gene fusion without a known acquired resistance mutation\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['if a patient with pancreatic adenocarcinoma has v::nrg1, one recommended therapy is zenocutuzumab. therapy type: targeted therapy. therapy strategy: nrg1 inhibition. indication: bizengri is a bispecific her2- and her3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with invasive breast carcinoma has egfr exon 20 (insertion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with non-small cell lung cancer has pr positive, her2-negative, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + oxaliplatin + capecitabine + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, one recommended therapy is carboplatin + gemcitabine + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antimetabolite + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic tnbc whose tumors express pd-l1 (cps >=10) as determined by an fda approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with high-risk early-stage triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is carboplatin + doxorubicin + paclitaxel + cyclophosphamide + pembrolizumab. therapy type: chemotherapy + chemotherapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + alkylating chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage tnbc in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with non-small cell lung cancer has egfr p.t790m, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + fluorouracil + cisplatin + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with unresectable or metastatic gastrointestinal stromal tumor has pdgfra p.d842v, one recommended therapy is avapritinib. therapy type: targeted therapy. therapy strategy: kit inhibition. indication: ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gist harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation, including pdgfra d842v mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, pten deletion, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: what fda-approved therapies exist for a stage iv pancreatic ductal adenocarcinoma patient with a ntrk mutation\n",
      "     \n",
      "    \n",
      "============= hybrid =============\n",
      "set()\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['if a patient with pancreatic adenocarcinoma has v::nrg1, one recommended therapy is zenocutuzumab. therapy type: targeted therapy. therapy strategy: nrg1 inhibition. indication: bizengri is a bispecific her2- and her3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with invasive breast carcinoma has egfr exon 20 (insertion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with non-small cell lung cancer has pr positive, her2-negative, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + oxaliplatin + capecitabine + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, one recommended therapy is carboplatin + gemcitabine + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antimetabolite + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic tnbc whose tumors express pd-l1 (cps >=10) as determined by an fda approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with high-risk early-stage triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is carboplatin + doxorubicin + paclitaxel + cyclophosphamide + pembrolizumab. therapy type: chemotherapy + chemotherapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + alkylating chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage tnbc in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with non-small cell lung cancer has egfr p.t790m, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + fluorouracil + cisplatin + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with unresectable or metastatic gastrointestinal stromal tumor has pdgfra p.d842v, one recommended therapy is avapritinib. therapy type: targeted therapy. therapy strategy: kit inhibition. indication: ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gist harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation, including pdgfra d842v mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, pten deletion, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: what fda-approved therapies exist for a stage iv pancreatic ductal adenocarcinoma patient with a ntrk mutation\n",
      "     \n",
      "    \n",
      "[{'index': 600, 'context': 'if a patient with pancreatic adenocarcinoma has v::nrg1, one recommended therapy is zenocutuzumab. therapy type: targeted therapy. therapy strategy: nrg1 inhibition. indication: bizengri is a bispecific her2- and her3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf', 'bm25_score': 0.23632192715512446, 'faiss_score': 0.8295938968658447, 'hybrid_score': 0.8295938968658447}, {'index': 433, 'context': 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'bm25_score': 0.2639535054916895, 'faiss_score': 0.8174058794975281, 'hybrid_score': 0.8174058794975281}, {'index': 434, 'context': 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'bm25_score': 0.26211673462178153, 'faiss_score': 0.8166108727455139, 'hybrid_score': 0.8166108727455139}, {'index': 435, 'context': 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'bm25_score': 0.22544865950114962, 'faiss_score': 0.816213071346283, 'hybrid_score': 0.816213071346283}, {'index': 139, 'context': 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'bm25_score': 0.2530802378377147, 'faiss_score': 0.8136392831802368, 'hybrid_score': 0.8136392831802368}, {'index': 140, 'context': 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'bm25_score': 0.25116102900818144, 'faiss_score': 0.812665581703186, 'hybrid_score': 0.812665581703186}, {'index': 228, 'context': 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'bm25_score': 0.22544865950114962, 'faiss_score': 0.8124617338180542, 'hybrid_score': 0.8124617338180542}, {'index': 229, 'context': 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'bm25_score': 0.2530802378377147, 'faiss_score': 0.8116613626480103, 'hybrid_score': 0.8116613626480103}, {'index': 138, 'context': 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'bm25_score': 0.25116102900818144, 'faiss_score': 0.8113576769828796, 'hybrid_score': 0.8113576769828796}, {'index': 230, 'context': 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'bm25_score': 0.22955657774699173, 'faiss_score': 0.81046062707901, 'hybrid_score': 0.81046062707901}, {'index': 636, 'context': 'if a patient with invasive breast carcinoma has egfr exon 20 (insertion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.25718815608355683, 'faiss_score': 0.8100000619888306, 'hybrid_score': 0.8100000619888306}, {'index': 638, 'context': 'if a patient with non-small cell lung cancer has pr positive, her2-negative, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.255324973187202, 'faiss_score': 0.8078091144561768, 'hybrid_score': 0.8078091144561768}, {'index': 376, 'context': 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + oxaliplatin + capecitabine + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'bm25_score': 0.23665067161595496, 'faiss_score': 0.8056490421295166, 'hybrid_score': 0.8056490421295166}, {'index': 397, 'context': 'if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, one recommended therapy is carboplatin + gemcitabine + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antimetabolite + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic tnbc whose tumors express pd-l1 (cps >=10) as determined by an fda approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'bm25_score': 0.26428224995252003, 'faiss_score': 0.8046600818634033, 'hybrid_score': 0.8046600818634033}, {'index': 395, 'context': 'if a patient with high-risk early-stage triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is carboplatin + doxorubicin + paclitaxel + cyclophosphamide + pembrolizumab. therapy type: chemotherapy + chemotherapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + alkylating chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage tnbc in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'bm25_score': 0.26215975989103685, 'faiss_score': 0.8046005964279175, 'hybrid_score': 0.8046005964279175}, {'index': 635, 'context': 'if a patient with non-small cell lung cancer has egfr p.t790m, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.4573050247930055, 'faiss_score': 0.8039265275001526, 'hybrid_score': 0.8039265275001526}, {'index': 375, 'context': 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + fluorouracil + cisplatin + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'bm25_score': 0.37441028978331015, 'faiss_score': 0.8023242950439453, 'hybrid_score': 0.8023242950439453}, {'index': 43, 'context': 'if a patient with unresectable or metastatic gastrointestinal stromal tumor has pdgfra p.d842v, one recommended therapy is avapritinib. therapy type: targeted therapy. therapy strategy: kit inhibition. indication: ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gist harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation, including pdgfra d842v mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf', 'bm25_score': 0.37441028978331015, 'faiss_score': 0.8017034530639648, 'hybrid_score': 0.8017034530639648}, {'index': 74, 'context': 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'bm25_score': 0.4573050247930055, 'faiss_score': 0.8015077710151672, 'hybrid_score': 0.8015077710151672}, {'index': 634, 'context': 'if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.2746396925771489, 'faiss_score': 0.8014819622039795, 'hybrid_score': 0.8014819622039795}, {'index': 72, 'context': 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'bm25_score': 0.2973905070146119, 'faiss_score': 0.8014775514602661, 'hybrid_score': 0.8014775514602661}, {'index': 639, 'context': 'if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.30808539853982925, 'faiss_score': 0.8014184236526489, 'hybrid_score': 0.8014184236526489}, {'index': 68, 'context': 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'bm25_score': 0.3012413652465754, 'faiss_score': 0.8008947372436523, 'hybrid_score': 0.8008947372436523}, {'index': 637, 'context': 'if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.3132129320246248, 'faiss_score': 0.8001244068145752, 'hybrid_score': 0.8001244068145752}, {'index': 77, 'context': 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, pten deletion, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'bm25_score': 0.37480363745632383, 'faiss_score': 0.7999020218849182, 'hybrid_score': 0.7999020218849182}]\n",
      "============= query =============\n",
      "(1, 7): what fda-approved therapies exist for a stage iv pancreatic ductal adenocarcinoma patient with a ntrk mutation\n",
      "============= ground-truth =============\n",
      "{frozenset({'larotrectinib'}), frozenset({'entrectinib'}), frozenset({'repotrectinib'})}\n",
      "============= dense =============\n",
      "{frozenset({'larotrectinib'}), frozenset({'entrectinib'}), frozenset({'repotrectinib'})}\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Pancreatic Ductal Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Stage IV\",\n",
      "        \"Drug Name\": \"Repotrectinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory alternative therapy\",\n",
      "        \"Genomic Features\": \"NTRK gene fusion\",\n",
      "        \"FDA-approval status\": \"Approved under accelerated approval based on overall response rate and duration of response\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Pancreatic Ductal Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Stage IV\",\n",
      "        \"Drug Name\": \"Entrectinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory alternative therapy\",\n",
      "        \"Genomic Features\": \"NTRK gene fusion\",\n",
      "        \"FDA-approval status\": \"Approved under accelerated approval based on tumor response rate and durability of response\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Pancreatic Ductal Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Stage IV\",\n",
      "        \"Drug Name\": \"Larotrectinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory alternative therapy\",\n",
      "        \"Genomic Features\": \"NTRK gene fusion\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['if a patient with pancreatic adenocarcinoma has v::nrg1, one recommended therapy is zenocutuzumab. therapy type: targeted therapy. therapy strategy: nrg1 inhibition. indication: bizengri is a bispecific her2- and her3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with invasive breast carcinoma has egfr exon 20 (insertion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with non-small cell lung cancer has pr positive, her2-negative, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + oxaliplatin + capecitabine + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, one recommended therapy is carboplatin + gemcitabine + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antimetabolite + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic tnbc whose tumors express pd-l1 (cps >=10) as determined by an fda approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with high-risk early-stage triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is carboplatin + doxorubicin + paclitaxel + cyclophosphamide + pembrolizumab. therapy type: chemotherapy + chemotherapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + alkylating chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage tnbc in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with non-small cell lung cancer has egfr p.t790m, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + fluorouracil + cisplatin + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with unresectable or metastatic gastrointestinal stromal tumor has pdgfra p.d842v, one recommended therapy is avapritinib. therapy type: targeted therapy. therapy strategy: kit inhibition. indication: ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gist harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation, including pdgfra d842v mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, pten deletion, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: what fda-approved therapies exist for a stage iv pancreatic ductal adenocarcinoma patient with a ntrk mutation\n",
      "     \n",
      "    \n",
      "============= hybrid =============\n",
      "set()\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['if a patient with pancreatic adenocarcinoma has v::nrg1, one recommended therapy is zenocutuzumab. therapy type: targeted therapy. therapy strategy: nrg1 inhibition. indication: bizengri is a bispecific her2- and her3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with invasive breast carcinoma has egfr exon 20 (insertion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with non-small cell lung cancer has pr positive, her2-negative, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + oxaliplatin + capecitabine + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, one recommended therapy is carboplatin + gemcitabine + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antimetabolite + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic tnbc whose tumors express pd-l1 (cps >=10) as determined by an fda approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with high-risk early-stage triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is carboplatin + doxorubicin + paclitaxel + cyclophosphamide + pembrolizumab. therapy type: chemotherapy + chemotherapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + alkylating chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage tnbc in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with non-small cell lung cancer has egfr p.t790m, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + fluorouracil + cisplatin + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with unresectable or metastatic gastrointestinal stromal tumor has pdgfra p.d842v, one recommended therapy is avapritinib. therapy type: targeted therapy. therapy strategy: kit inhibition. indication: ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gist harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation, including pdgfra d842v mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, pten deletion, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: what fda-approved therapies exist for a stage iv pancreatic ductal adenocarcinoma patient with a ntrk mutation\n",
      "     \n",
      "    \n",
      "[{'index': 600, 'context': 'if a patient with pancreatic adenocarcinoma has v::nrg1, one recommended therapy is zenocutuzumab. therapy type: targeted therapy. therapy strategy: nrg1 inhibition. indication: bizengri is a bispecific her2- and her3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf', 'bm25_score': 0.23632192715512446, 'faiss_score': 0.8295938968658447, 'hybrid_score': 0.8295938968658447}, {'index': 433, 'context': 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'bm25_score': 0.2639535054916895, 'faiss_score': 0.8174058794975281, 'hybrid_score': 0.8174058794975281}, {'index': 434, 'context': 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'bm25_score': 0.26211673462178153, 'faiss_score': 0.8166108727455139, 'hybrid_score': 0.8166108727455139}, {'index': 435, 'context': 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'bm25_score': 0.22544865950114962, 'faiss_score': 0.816213071346283, 'hybrid_score': 0.816213071346283}, {'index': 139, 'context': 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'bm25_score': 0.2530802378377147, 'faiss_score': 0.8136392831802368, 'hybrid_score': 0.8136392831802368}, {'index': 140, 'context': 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'bm25_score': 0.25116102900818144, 'faiss_score': 0.812665581703186, 'hybrid_score': 0.812665581703186}, {'index': 228, 'context': 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'bm25_score': 0.22544865950114962, 'faiss_score': 0.8124617338180542, 'hybrid_score': 0.8124617338180542}, {'index': 229, 'context': 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'bm25_score': 0.2530802378377147, 'faiss_score': 0.8116613626480103, 'hybrid_score': 0.8116613626480103}, {'index': 138, 'context': 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'bm25_score': 0.25116102900818144, 'faiss_score': 0.8113576769828796, 'hybrid_score': 0.8113576769828796}, {'index': 230, 'context': 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'bm25_score': 0.22955657774699173, 'faiss_score': 0.81046062707901, 'hybrid_score': 0.81046062707901}, {'index': 636, 'context': 'if a patient with invasive breast carcinoma has egfr exon 20 (insertion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.25718815608355683, 'faiss_score': 0.8100000619888306, 'hybrid_score': 0.8100000619888306}, {'index': 638, 'context': 'if a patient with non-small cell lung cancer has pr positive, her2-negative, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.255324973187202, 'faiss_score': 0.8078091144561768, 'hybrid_score': 0.8078091144561768}, {'index': 376, 'context': 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + oxaliplatin + capecitabine + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'bm25_score': 0.23665067161595496, 'faiss_score': 0.8056490421295166, 'hybrid_score': 0.8056490421295166}, {'index': 397, 'context': 'if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, one recommended therapy is carboplatin + gemcitabine + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antimetabolite + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic tnbc whose tumors express pd-l1 (cps >=10) as determined by an fda approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'bm25_score': 0.26428224995252003, 'faiss_score': 0.8046600818634033, 'hybrid_score': 0.8046600818634033}, {'index': 395, 'context': 'if a patient with high-risk early-stage triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is carboplatin + doxorubicin + paclitaxel + cyclophosphamide + pembrolizumab. therapy type: chemotherapy + chemotherapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + alkylating chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage tnbc in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'bm25_score': 0.26215975989103685, 'faiss_score': 0.8046005964279175, 'hybrid_score': 0.8046005964279175}, {'index': 635, 'context': 'if a patient with non-small cell lung cancer has egfr p.t790m, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.4573050247930055, 'faiss_score': 0.8039265275001526, 'hybrid_score': 0.8039265275001526}, {'index': 375, 'context': 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + fluorouracil + cisplatin + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'bm25_score': 0.37441028978331015, 'faiss_score': 0.8023242950439453, 'hybrid_score': 0.8023242950439453}, {'index': 43, 'context': 'if a patient with unresectable or metastatic gastrointestinal stromal tumor has pdgfra p.d842v, one recommended therapy is avapritinib. therapy type: targeted therapy. therapy strategy: kit inhibition. indication: ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gist harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation, including pdgfra d842v mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf', 'bm25_score': 0.37441028978331015, 'faiss_score': 0.8017034530639648, 'hybrid_score': 0.8017034530639648}, {'index': 74, 'context': 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'bm25_score': 0.4573050247930055, 'faiss_score': 0.8015077710151672, 'hybrid_score': 0.8015077710151672}, {'index': 634, 'context': 'if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.2746396925771489, 'faiss_score': 0.8014819622039795, 'hybrid_score': 0.8014819622039795}, {'index': 72, 'context': 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'bm25_score': 0.2973905070146119, 'faiss_score': 0.8014775514602661, 'hybrid_score': 0.8014775514602661}, {'index': 639, 'context': 'if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.30808539853982925, 'faiss_score': 0.8014184236526489, 'hybrid_score': 0.8014184236526489}, {'index': 68, 'context': 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'bm25_score': 0.3012413652465754, 'faiss_score': 0.8008947372436523, 'hybrid_score': 0.8008947372436523}, {'index': 637, 'context': 'if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.3132129320246248, 'faiss_score': 0.8001244068145752, 'hybrid_score': 0.8001244068145752}, {'index': 77, 'context': 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, pten deletion, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'bm25_score': 0.37480363745632383, 'faiss_score': 0.7999020218849182, 'hybrid_score': 0.7999020218849182}]\n",
      "============= query =============\n",
      "(2, 7): what fda-approved therapies exist for a stage iv pancreatic ductal adenocarcinoma patient with a ntrk mutation\n",
      "============= ground-truth =============\n",
      "{frozenset({'larotrectinib'}), frozenset({'entrectinib'}), frozenset({'repotrectinib'})}\n",
      "============= dense =============\n",
      "{frozenset({'larotrectinib'}), frozenset({'entrectinib'}), frozenset({'repotrectinib'})}\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Pancreatic Ductal Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Stage IV\",\n",
      "        \"Drug Name\": \"Repotrectinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory alternative therapy\",\n",
      "        \"Genomic Features\": \"NTRK gene fusion\",\n",
      "        \"FDA-approval status\": \"Approved under accelerated approval based on overall response rate and duration of response\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Pancreatic Ductal Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Stage IV\",\n",
      "        \"Drug Name\": \"Entrectinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory alternative therapy\",\n",
      "        \"Genomic Features\": \"NTRK gene fusion\",\n",
      "        \"FDA-approval status\": \"Approved under accelerated approval based on tumor response rate and durability of response\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Pancreatic Ductal Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Stage IV\",\n",
      "        \"Drug Name\": \"Larotrectinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or that have progressed following treatment\",\n",
      "        \"Genomic Features\": \"NTRK gene fusion without a known acquired resistance mutation\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['if a patient with pancreatic adenocarcinoma has v::nrg1, one recommended therapy is zenocutuzumab. therapy type: targeted therapy. therapy strategy: nrg1 inhibition. indication: bizengri is a bispecific her2- and her3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with invasive breast carcinoma has egfr exon 20 (insertion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with non-small cell lung cancer has pr positive, her2-negative, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + oxaliplatin + capecitabine + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, one recommended therapy is carboplatin + gemcitabine + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antimetabolite + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic tnbc whose tumors express pd-l1 (cps >=10) as determined by an fda approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with high-risk early-stage triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is carboplatin + doxorubicin + paclitaxel + cyclophosphamide + pembrolizumab. therapy type: chemotherapy + chemotherapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + alkylating chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage tnbc in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with non-small cell lung cancer has egfr p.t790m, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + fluorouracil + cisplatin + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with unresectable or metastatic gastrointestinal stromal tumor has pdgfra p.d842v, one recommended therapy is avapritinib. therapy type: targeted therapy. therapy strategy: kit inhibition. indication: ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gist harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation, including pdgfra d842v mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, pten deletion, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: what fda-approved therapies exist for a stage iv pancreatic ductal adenocarcinoma patient with a ntrk mutation\n",
      "     \n",
      "    \n",
      "============= hybrid =============\n",
      "set()\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['if a patient with pancreatic adenocarcinoma has v::nrg1, one recommended therapy is zenocutuzumab. therapy type: targeted therapy. therapy strategy: nrg1 inhibition. indication: bizengri is a bispecific her2- and her3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'if a patient with invasive breast carcinoma has egfr exon 20 (insertion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with non-small cell lung cancer has pr positive, her2-negative, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + oxaliplatin + capecitabine + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, one recommended therapy is carboplatin + gemcitabine + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antimetabolite + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic tnbc whose tumors express pd-l1 (cps >=10) as determined by an fda approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with high-risk early-stage triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is carboplatin + doxorubicin + paclitaxel + cyclophosphamide + pembrolizumab. therapy type: chemotherapy + chemotherapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + alkylating chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage tnbc in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with non-small cell lung cancer has egfr p.t790m, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + fluorouracil + cisplatin + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'if a patient with unresectable or metastatic gastrointestinal stromal tumor has pdgfra p.d842v, one recommended therapy is avapritinib. therapy type: targeted therapy. therapy strategy: kit inhibition. indication: ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gist harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation, including pdgfra d842v mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, pten deletion, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: what fda-approved therapies exist for a stage iv pancreatic ductal adenocarcinoma patient with a ntrk mutation\n",
      "     \n",
      "    \n",
      "[{'index': 600, 'context': 'if a patient with pancreatic adenocarcinoma has v::nrg1, one recommended therapy is zenocutuzumab. therapy type: targeted therapy. therapy strategy: nrg1 inhibition. indication: bizengri is a bispecific her2- and her3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf', 'bm25_score': 0.23632192715512446, 'faiss_score': 0.8295938968658447, 'hybrid_score': 0.8295938968658447}, {'index': 433, 'context': 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'bm25_score': 0.2639535054916895, 'faiss_score': 0.8174058794975281, 'hybrid_score': 0.8174058794975281}, {'index': 434, 'context': 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'bm25_score': 0.26211673462178153, 'faiss_score': 0.8166108727455139, 'hybrid_score': 0.8166108727455139}, {'index': 435, 'context': 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is repotrectinib. therapy type: targeted therapy. therapy strategy: ros inhibition. indication: augtyro is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (ntrk) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'bm25_score': 0.22544865950114962, 'faiss_score': 0.816213071346283, 'hybrid_score': 0.816213071346283}, {'index': 139, 'context': 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'bm25_score': 0.2530802378377147, 'faiss_score': 0.8136392831802368, 'hybrid_score': 0.8136392831802368}, {'index': 140, 'context': 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'bm25_score': 0.25116102900818144, 'faiss_score': 0.812665581703186, 'hybrid_score': 0.812665581703186}, {'index': 228, 'context': 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'bm25_score': 0.22544865950114962, 'faiss_score': 0.8124617338180542, 'hybrid_score': 0.8124617338180542}, {'index': 229, 'context': 'if a patient with any solid tumor has v::ntrk2, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'bm25_score': 0.2530802378377147, 'faiss_score': 0.8116613626480103, 'hybrid_score': 0.8116613626480103}, {'index': 138, 'context': 'if a patient with any solid tumor has v::ntrk1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'bm25_score': 0.25116102900818144, 'faiss_score': 0.8113576769828796, 'hybrid_score': 0.8113576769828796}, {'index': 230, 'context': 'if a patient with any solid tumor has v::ntrk3, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'bm25_score': 0.22955657774699173, 'faiss_score': 0.81046062707901, 'hybrid_score': 0.81046062707901}, {'index': 636, 'context': 'if a patient with invasive breast carcinoma has egfr exon 20 (insertion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.25718815608355683, 'faiss_score': 0.8100000619888306, 'hybrid_score': 0.8100000619888306}, {'index': 638, 'context': 'if a patient with non-small cell lung cancer has pr positive, her2-negative, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.255324973187202, 'faiss_score': 0.8078091144561768, 'hybrid_score': 0.8078091144561768}, {'index': 376, 'context': 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + oxaliplatin + capecitabine + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'bm25_score': 0.23665067161595496, 'faiss_score': 0.8056490421295166, 'hybrid_score': 0.8056490421295166}, {'index': 397, 'context': 'if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, one recommended therapy is carboplatin + gemcitabine + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antimetabolite + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic tnbc whose tumors express pd-l1 (cps >=10) as determined by an fda approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'bm25_score': 0.26428224995252003, 'faiss_score': 0.8046600818634033, 'hybrid_score': 0.8046600818634033}, {'index': 395, 'context': 'if a patient with high-risk early-stage triple-negative invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is carboplatin + doxorubicin + paclitaxel + cyclophosphamide + pembrolizumab. therapy type: chemotherapy + chemotherapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + topoisomerase inhibition + taxane-based chemotherapy + alkylating chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage tnbc in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'bm25_score': 0.26215975989103685, 'faiss_score': 0.8046005964279175, 'hybrid_score': 0.8046005964279175}, {'index': 635, 'context': 'if a patient with non-small cell lung cancer has egfr p.t790m, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.4573050247930055, 'faiss_score': 0.8039265275001526, 'hybrid_score': 0.8039265275001526}, {'index': 375, 'context': 'if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + fluorouracil + cisplatin + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps >=1) as determined by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'bm25_score': 0.37441028978331015, 'faiss_score': 0.8023242950439453, 'hybrid_score': 0.8023242950439453}, {'index': 43, 'context': 'if a patient with unresectable or metastatic gastrointestinal stromal tumor has pdgfra p.d842v, one recommended therapy is avapritinib. therapy type: targeted therapy. therapy strategy: kit inhibition. indication: ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gist harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation, including pdgfra d842v mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf', 'bm25_score': 0.37441028978331015, 'faiss_score': 0.8017034530639648, 'hybrid_score': 0.8017034530639648}, {'index': 74, 'context': 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'bm25_score': 0.4573050247930055, 'faiss_score': 0.8015077710151672, 'hybrid_score': 0.8015077710151672}, {'index': 634, 'context': 'if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.2746396925771489, 'faiss_score': 0.8014819622039795, 'hybrid_score': 0.8014819622039795}, {'index': 72, 'context': 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'bm25_score': 0.2973905070146119, 'faiss_score': 0.8014775514602661, 'hybrid_score': 0.8014775514602661}, {'index': 639, 'context': 'if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.30808539853982925, 'faiss_score': 0.8014184236526489, 'hybrid_score': 0.8014184236526489}, {'index': 68, 'context': 'if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'bm25_score': 0.3012413652465754, 'faiss_score': 0.8008947372436523, 'hybrid_score': 0.8008947372436523}, {'index': 637, 'context': 'if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'bm25_score': 0.3132129320246248, 'faiss_score': 0.8001244068145752, 'hybrid_score': 0.8001244068145752}, {'index': 77, 'context': 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, pten deletion, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'bm25_score': 0.37480363745632383, 'faiss_score': 0.7999020218849182, 'hybrid_score': 0.7999020218849182}]\n"
     ]
    }
   ],
   "source": [
    "for i in range(5):\n",
    "    idx=all_results_idx[i]['A_success_B_failed']\n",
    "    for j in idx:\n",
    "        print(\"============= query =============\")\n",
    "        print(f\"{i,  j}: {evaluator_val_queries.query['prompt'][j]}\")\n",
    "        print(\"============= ground-truth =============\")\n",
    "        print(evaluator_val_queries.evals['RAG']['dense']['5'][i]['true_drugs_generic_set_ls'][j])\n",
    "        print(\"============= dense =============\")\n",
    "        print(evaluator_val_queries.evals['RAG']['dense']['5'][i]['pred_drugs_generic_set_ls'][j])\n",
    "        print(evaluator_val_queries.llm_output['RAG']['dense']['5'][i][j])\n",
    "        print(evaluator_val_queries.llm_input['RAG']['dense']['5'][i][j])\n",
    "        print(\"============= hybrid =============\")\n",
    "        print(evaluator_val_queries.evals['RAG']['hybrid']['5'][i]['pred_drugs_generic_set_ls'][j])\n",
    "        # print(evaluator_val_queries.llm_output['RAG']['hybrid']['5'][i][j])\n",
    "        print(evaluator_val_queries.llm_input['RAG']['hybrid']['5'][i][j])\n",
    "        print(evaluator_val_queries.retrieval['RAG']['hybrid']['5'][i][j]['retrieval_results'][0]['retrieved_df'])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "910f89ee",
   "metadata": {},
   "source": [
    "Inspect why hybrid failed question 19"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "388663d5",
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_retrieved_context(text):\n",
    "    start_idx=text.find(\"[\")\n",
    "    end_idx=text.find(\"]\")+1\n",
    "    list_str=text[start_idx:end_idx]\n",
    "    context_list=ast.literal_eval(list_str)\n",
    "    return(context_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8ad72ed5",
   "metadata": {},
   "outputs": [],
   "source": [
    "#dense\n",
    "extract_retrieved_context(evaluator_val_queries.llm_input['RAG']['dense']['5'][0][19])[0:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "aee8d78b",
   "metadata": {},
   "outputs": [],
   "source": [
    "#hybrid\n",
    "evaluator_val_queries.retrieval['RAG']['hybrid']['5'][0][19]['retrieval_results'][0]['retrieved_df'][0:5]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8e3adb05",
   "metadata": {},
   "source": [
    "Both failed:\n",
    "- 7 (1/5) (what fda-approved therapies exist for a stage iv pancreatic ductal adenocarcinoma patient with a ntrk mutation) \\\n",
    "    : context retrieved, LLM answer incorrect -> hybrid gets it right, but not always -> there's a difference between ntrk mutation and ntrk fusion -> context explicitly says it's fusion but the query is not explicit enough\n",
    "\n",
    "Dense failed Hybrid success:\n",
    "- 7 (1/5)\n",
    "\n",
    "Dense success hybrid failed:\n",
    "- 7 (1/5)\n",
    "- 19 (3/5) (i have a patient with metastatic hr-negative, her2-low, pd-l1-negative, breast cancer with no germline brca mutation.  for second line, is t-dxd or sacituzumab govitecan preferred?) \\\n",
    "    : context retrieved -> \n",
    "        1) LLM misinterpretation due to context order (some lung contexts are on the top)?\n",
    "        2) is this a rare case where hr-positive drug is used for hr-negative case?\n",
    "\n",
    "Takeaway:\n",
    "- But both worked quite well in getting at least one drug correct (partial match acc) on the real-world validation queries. There is one unusual case where the query query asks for hr-negative breast cancer case but the ground-truth drug is approved for hr-positive cases.\n",
    "- It's also hard to conclude because most queries does not have FDA-approved drugs.\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d33b2442",
   "metadata": {},
   "source": [
    "#### Exact match error analysis results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "fa2a6c1e",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_results_idx = []\n",
    "for i in range(5): \n",
    "    dense_partial_failed = ~np.array(evaluator_val_queries.evals['RAG']['dense']['5'][i]['exact_match_acc'])\n",
    "    hybrid_partial_failed = ~np.array(evaluator_val_queries.evals['RAG']['hybrid']['5'][i]['exact_match_acc'])\n",
    "    all_results_idx.append(compare_mode_A_vs_B_idx(dense_partial_failed, hybrid_partial_failed))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "344c0e1d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "count",
         "rawType": "int64",
         "type": "integer"
        }
       ],
       "ref": "575e69db-b9e8-46f6-9bd2-8b733c02ba87",
       "rows": [
        [
         "3",
         "5"
        ],
        [
         "17",
         "5"
        ],
        [
         "18",
         "5"
        ],
        [
         "7",
         "2"
        ]
       ],
       "shape": {
        "columns": 1,
        "rows": 4
       }
      },
      "text/plain": [
       "3     5\n",
       "17    5\n",
       "18    5\n",
       "7     2\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_runs=[all_results_idx[i]['both_failed'] for i in range(5)]\n",
    "pd.Series([x for run in all_runs for x in run]).value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "e24426a4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "count",
         "rawType": "int64",
         "type": "integer"
        }
       ],
       "ref": "980b073a-319c-40a4-a47c-f2691bf5c0ea",
       "rows": [],
       "shape": {
        "columns": 1,
        "rows": 0
       }
      },
      "text/plain": [
       "Series([], Name: count, dtype: int64)"
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_runs=[all_results_idx[i]['A_failed_B_success'] for i in range(5)]\n",
    "pd.Series([x for run in all_runs for x in run]).value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "2cc445e7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "count",
         "rawType": "int64",
         "type": "integer"
        }
       ],
       "ref": "38fccc8d-5c5e-43d7-9d88-b865e47230ed",
       "rows": [
        [
         "7",
         "3"
        ]
       ],
       "shape": {
        "columns": 1,
        "rows": 1
       }
      },
      "text/plain": [
       "7    3\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_runs=[all_results_idx[i]['A_success_B_failed'] for i in range(5)]\n",
    "pd.Series([x for run in all_runs for x in run]).value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "f77c802f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "============= query =============\n",
      "(0, 17): i have a patient with de novo metastatic hr+ breast cancer with both a somatic akt mutation and a germline brca2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n",
      "============= ground-truth =============\n",
      "{frozenset({'fulvestrant', 'capivasertib'}), frozenset({'olaparib'}), frozenset({'talazoparib'})}\n",
      "============= dense =============\n",
      "{frozenset({'fulvestrant', 'capivasertib'}), frozenset({'olaparib'})}\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['if a patient with metastatic invasive breast carcinoma has her2-negative, brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious gbrcam, her2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. patients with hormone receptor (hr)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with metastatic invasive breast carcinoma has her2-negative, brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious gbrcam, her2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. patients with hormone receptor (hr)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, akt1 somatic variants, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with metastatic pancreatic adenocarcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gbrcam metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with unresectable or metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic her2-positive (ihc 3+ or ish positive) breast cancer who have received a prior anti-her2-based regimen either (i) in the metastatic setting, or (ii) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, akt1 somatic variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has akt1 somatic variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with metastatic pancreatic adenocarcinoma has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gbrcam metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 oncogenic variants, one recommended therapy is prednisone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with advanced peritoneal serous carcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 oncogenic variants, one recommended therapy is prednisolone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 pathogenic variants, one recommended therapy is prednisolone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with advanced peritoneal serous carcinoma has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 pathogenic variants, one recommended therapy is prednisone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with metastatic gastrointestinal stromal tumor has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is a her2/neu receptor antagonist indicated for the treatment of her2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. select patients for therapy based on an fda-approved companion diagnostic for herceptin. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf', 'if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 pathogenic variants, one recommended therapy is prednisone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with unresectable or metastatic invasive breast carcinoma has her2-low, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic her2-low (ihc 1+ or ihc 2+/ish-) breast cancer, as determined by an fda-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf', 'if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 oncogenic variants, one recommended therapy is prednisone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, brca1 pathogenic variants, one recommended therapy is talazoparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline brca-mutated (gbrcam) her2-negative locally advanced or metastatic breast cancer. select patients for therapy based on an fda-approved companion diagnostic for talzenna. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, brca2 pathogenic variants, one recommended therapy is talazoparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline brca-mutated (gbrcam) her2-negative locally advanced or metastatic breast cancer. select patients for therapy based on an fda-approved companion diagnostic for talzenna. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'if a patient with high risk early invasive breast carcinoma has her2-negative, brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is margetuximab + gemcitabine. therapy type: hormone therapy + chemotherapy. therapy strategy: her2 inhibition + antimetabolite. indication: margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf', 'if a patient with high risk early invasive breast carcinoma has her2-negative, brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: i have a patient with de novo metastatic hr+ breast cancer with both a somatic akt mutation and a germline brca2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n",
      "     \n",
      "    \n",
      "============= hybrid =============\n",
      "{frozenset({'fulvestrant', 'capivasertib'}), frozenset({'olaparib'})}\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['if a patient with metastatic invasive breast carcinoma has her2-negative, brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious gbrcam, her2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. patients with hormone receptor (hr)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, brca2 pathogenic variants, one recommended therapy is talazoparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline brca-mutated (gbrcam) her2-negative locally advanced or metastatic breast cancer. select patients for therapy based on an fda-approved companion diagnostic for talzenna. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'if a patient with metastatic invasive breast carcinoma has her2-negative, brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious gbrcam, her2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. patients with hormone receptor (hr)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with unresectable or metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic her2-positive (ihc 3+ or ish positive) breast cancer who have received a prior anti-her2-based regimen either (i) in the metastatic setting, or (ii) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf', 'if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is margetuximab + gemcitabine. therapy type: hormone therapy + chemotherapy. therapy strategy: her2 inhibition + antimetabolite. indication: margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf', 'if a patient with high risk early invasive breast carcinoma has her2-negative, brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, brca1 pathogenic variants, one recommended therapy is talazoparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline brca-mutated (gbrcam) her2-negative locally advanced or metastatic breast cancer. select patients for therapy based on an fda-approved companion diagnostic for talzenna. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is margetuximab + vinorelbine. therapy type: hormone therapy + chemotherapy. therapy strategy: her2 inhibition + vinca alkaloid chemotherapy. indication: margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf', 'if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is eribulin + margetuximab. therapy type: chemotherapy + hormone therapy. therapy strategy: tubulin polymerization inhibition + her2 inhibition. indication: margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf', 'if a patient with unresectable or metastatic invasive breast carcinoma has her2-low, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic her2-low (ihc 1+ or ihc 2+/ish-) breast cancer, as determined by an fda-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has akt1 somatic variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with advanced peritoneal serous carcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with advanced peritoneal serous carcinoma has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with high risk early invasive breast carcinoma has her2-negative, brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has akt1 amplification, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with relapsed peritoneal serous carcinoma has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has akt1 amplification, pr positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, akt1 somatic variants, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has akt1 amplification, pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, akt1 somatic variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'if a patient with metastatic pancreatic adenocarcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gbrcam metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is a her2/neu receptor antagonist indicated for the treatment of her2 -overexpressing breast cancer. select patients for therapy based on an fda-approved companion diagnostic for herceptin. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf', 'if a patient with early invasive breast carcinoma has her2-negative, er positive, one recommended therapy is goserelin + anastrozole + ribociclib. therapy type: hormone therapy + hormone therapy + targeted therapy. therapy strategy: gonadotropin-releasing hormone (gnrh) agonist + aromatase inhibition + cdk4/6 inhibition. indication: kisqali is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative stage ii and iii early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092orig1s018lbl.pdf']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: i have a patient with de novo metastatic hr+ breast cancer with both a somatic akt mutation and a germline brca2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n",
      "     \n",
      "    \n"
     ]
    }
   ],
   "source": [
    "for i in range(5):\n",
    "    idx=all_results_idx[i]['both_failed']\n",
    "    for j in idx:\n",
    "        if j == 17:\n",
    "            print(\"============= query =============\")\n",
    "            print(f\"{i,  j}: {evaluator_val_queries.query['prompt'][j]}\")\n",
    "            print(\"============= ground-truth =============\")\n",
    "            print(evaluator_val_queries.evals['RAG']['dense']['5'][i]['true_drugs_generic_set_ls'][j])\n",
    "            print(\"============= dense =============\")\n",
    "            print(evaluator_val_queries.evals['RAG']['dense']['5'][i]['pred_drugs_generic_set_ls'][j])\n",
    "            # print(evaluator_val_queries.llm_output['RAG']['dense']['5'][i][j])\n",
    "            print(evaluator_val_queries.llm_input['RAG']['dense']['5'][i][j])\n",
    "            print(\"============= hybrid =============\")\n",
    "            print(evaluator_val_queries.evals['RAG']['hybrid']['5'][i]['pred_drugs_generic_set_ls'][j])\n",
    "            # print(evaluator_val_queries.llm_output['RAG']['hybrid']['5'][i][j])\n",
    "            print(evaluator_val_queries.llm_input['RAG']['hybrid']['5'][i][j])\n",
    "            # print(evaluator_val_queries.retrieval['RAG']['hybrid']['5'][i][j]['retrieval_results'][0]['retrieved_df'])\n",
    "    break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "28b02542",
   "metadata": {},
   "outputs": [],
   "source": [
    "extract_retrieved_context(evaluator_val_queries.llm_input['RAG']['dense']['5'][0][7])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8a27fc0f",
   "metadata": {},
   "outputs": [],
   "source": [
    "evaluator_val_queries.retrieval['RAG']['hybrid']['5'][0][3]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0b25446f",
   "metadata": {},
   "source": [
    "Both failed:\n",
    "- 3 (5/5) (for a patient with cancer metastatic prostate cancer, advanced stage (most often stage iv, but some stage iii or earlier potentially) and with brca2 mutation, what drugs approved?) \\\n",
    "    : context retrieved incomplete -> missing prednisolone + abiraterone acetate + *niraparib* (probably due to the fact that there are many biomarker-linked drugs approved for prostate cancer) -> this is mainly due to an error in the database (missing BRCA-linked relationship for prednisolone + abiraterone acetate + niraparib) -> Brendan will update the db\n",
    "- 17 (5/5) (i have a patient with de novo metastatic hr+ breast cancer with both a somatic akt mutation and a germline brca2 mutation - what are the standard, recommended first- and second-line treatments for this patient?) \\\n",
    "    : context retrieved -> llm failed to retrieve *talazoparib*, which was in the lower part of the context list\n",
    "    -> after adding fuzzy matching *talazoparib* is now on the top part of the list but the llm is still misinterpreting, why?\n",
    "- 18 (5/5) (i have a patient with an initial diagnosis of ct3n1 her2+ breast cancer who received neoadjuvant tchp and had 1cm of residual disease at surgery. what is the recommended adjuvant treatment for this patient and what are the clinical trials that i should consider?) \\\n",
    "    : context mostly retrieved (hybrid context retrieved better than dense in terms of order of relevant contexts) -> LLM recall failure, retrieved trastuzumab emtansine only, probably because of query specificity (query: \"neoadjuvant TCHP\" -> kadcyla or trastuzumab emtansine: \"...after neoadjuvant ... treatment\"), heavily biasing llm's retrieval toward trastuzumab emtansine. it failed to generalize to other related therapies like neratinib, trastuzumab deruxtecan, and trastuzumab + pertuzumab\n",
    "- 7 (1/5) -> for this i tried increasing temperature to 0.2, which then LLM retrieved these drugs\n",
    "\n",
    "Dense failed hybrid success:\n",
    "- 7 (1/5)\n",
    "\n",
    "Dense success hybrid failed:\n",
    "- 7 (1/5), 19 (4/5)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d2dc313b",
   "metadata": {},
   "source": [
    "Key Takeaways:\n",
    "- Both dense and hybrid methods performed quite well in terms of partial recall (partial match acc)\n",
    "- Dense outperformed hybrid in query 19 with with HER2-low, HR-negative breast cancer, which is an edge case "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a2012d68",
   "metadata": {},
   "source": [
    "## Real-world query evaluation"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d8a2b3fe",
   "metadata": {},
   "source": [
    "### Define evaluation metrics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "c12a6c2d",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Define evaluation keys\n",
    "METRICS = {\n",
    "    \"exact\": \"avg_exact_match_acc\",\n",
    "    \"partial\": \"avg_partial_match_acc\",\n",
    "    \"precision\": \"avg_precision\",\n",
    "    \"recall\": \"avg_recall\",\n",
    "    \"f1\": \"avg_f1\",\n",
    "    \"specificity\": \"avg_specificity\"\n",
    "}"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "bc48790d",
   "metadata": {},
   "source": [
    "### Dense-only vs. Hybrid"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "ddcbb86d",
   "metadata": {},
   "outputs": [],
   "source": [
    "num_iter = 5\n",
    "strategies = [\"5\"]\n",
    "DENSE_FILEPATH='output/RAG_res_gpt4o_default/structured_realworld_test_v2_dense'\n",
    "HYBRID_FILEPATH='output/RAG_res_gpt4o_default/structured_realworld_test_v2_hybrid'\n",
    "QUERY_TEST = pd.read_csv(f\"data/real_world_db/real_world_test__v2.csv\", index_col=0)\n",
    "QUERY_TRUE = load_object(\"data/real_world_db/real_world_query_therapy_pair_dict.pkl\")\n",
    "\n",
    "mode_paths = {\n",
    "    \"dense\": DENSE_FILEPATH,\n",
    "    \"hybrid\": HYBRID_FILEPATH\n",
    "}\n",
    "\n",
    "evaluator_all_queries = Evaluator(\n",
    "    pipelines=['RAG'],\n",
    "    strategies=strategies,\n",
    "    metrics=METRICS,\n",
    "    query=QUERY_TEST,\n",
    "    true_dict=QUERY_TRUE,\n",
    "    mode_paths=mode_paths,\n",
    "    num_iter=num_iter\n",
    ")\n",
    "\n",
    "evaluator_all_queries.run()\n",
    "average = evaluator_all_queries.average()\n",
    "\n",
    "all_queries_results=evaluator_all_queries.results['RAG']\n",
    "all_queries_average=average['RAG']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "04f69e55",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 500x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "cols = sns.color_palette(cc.glasbey)\n",
    "\n",
    "eval_metrics_text = dict(zip(METRICS.keys(),\n",
    "                             ['Exact accuracy','Partial accuracy','Precision','Recall','F1 Score','Specificity']))\n",
    "\n",
    "plot_results = {\n",
    "    'RAG + dense-only': {k: v['5']*100 for k, v in all_queries_average['dense'].items()},\n",
    "    'RAG + hybrid': {k: v['5']*100 for k, v in all_queries_average['hybrid'].items()},\n",
    "}\n",
    "\n",
    "plot_radar_chart(\n",
    "    eval_results=plot_results, \n",
    "    metrics=eval_metrics_text.keys(), \n",
    "    metric_labels=eval_metrics_text,\n",
    "    title=None,\n",
    "    colors=[cols[6],cols[0]]\n",
    "    )"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "83f62a76",
   "metadata": {},
   "source": [
    "### Group queries\n",
    "- All vs. Queries within scope (asking biomarker-associated, FDA approved drugs)\n",
    "- Including single biomarker vs. multiple biomarkers vs. biomarkers with unknown significance\n",
    "- Queries within scope vs. tumor-agnostic queries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "id": "b38c899a",
   "metadata": {},
   "outputs": [],
   "source": [
    "QUERY_RAW=pd.read_csv(f\"data/real_world_db/updated_real_world_queries_answers__v1.csv\")\n",
    "QUERY_RAW=QUERY_RAW.dropna(subset='Questions').reset_index(drop=True)\n",
    "\n",
    "query_in_scope=QUERY_RAW[\n",
    "    (QUERY_RAW['Asking_genomic_biomarker_linked_therapy']==True) &\n",
    "    (QUERY_RAW['Asking_therapy']==True)\n",
    "    ].index.tolist()\n",
    "\n",
    "query_multiple_biomarkers=QUERY_RAW[\n",
    "    (QUERY_RAW['Asking_genomic_biomarker_linked_therapy']==True) &\n",
    "    (QUERY_RAW['Asking_therapy']==True) &\n",
    "    (QUERY_RAW['Multiple_biomarkers']==True)\n",
    "    ].index.tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "id": "7c6b99b3",
   "metadata": {},
   "outputs": [],
   "source": [
    "# add boolean columns to group queries\n",
    "QUERY_TEST.loc[QUERY_TEST.index.isin(query_in_scope), 'within_scope']=True\n",
    "QUERY_TEST.loc[QUERY_TEST.index.isin(query_multiple_biomarkers), 'multiple_biomarkers']=True"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "80548108",
   "metadata": {},
   "source": [
    "#### All queries (n=90) vs. Queries within scope (n=83)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "id": "766f6513",
   "metadata": {},
   "outputs": [],
   "source": [
    "# get appropriate indices\n",
    "QUERY_TEST_REINDEXED=QUERY_TEST.reset_index()\n",
    "within_scope_ind=QUERY_TEST_REINDEXED[\n",
    "    QUERY_TEST_REINDEXED['index']\n",
    "    .isin(QUERY_TEST[QUERY_TEST['within_scope']==True].index)\n",
    "    ].index.tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "id": "6d374f26",
   "metadata": {},
   "outputs": [],
   "source": [
    "num_iter = 5\n",
    "strategies = [\"5\"]\n",
    "\n",
    "mode_paths = {\n",
    "    \"dense\": DENSE_FILEPATH,\n",
    "    \"hybrid\": HYBRID_FILEPATH\n",
    "}\n",
    "\n",
    "evaluator_within_scope_queries = Evaluator(\n",
    "    pipelines=['RAG'],\n",
    "    strategies=strategies,\n",
    "    metrics=METRICS,\n",
    "    query=QUERY_TEST_REINDEXED,\n",
    "    true_dict=QUERY_TRUE,\n",
    "    mode_paths=mode_paths,\n",
    "    num_iter=num_iter,\n",
    "    subset_idx=within_scope_ind\n",
    ")\n",
    "evaluator_within_scope_queries.run()\n",
    "average = evaluator_within_scope_queries.average()\n",
    "within_scope_queries_results=evaluator_within_scope_queries.results['RAG']\n",
    "within_scope_queries_average=average['RAG']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f510e3d1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 500x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "cols=sns.color_palette(cc.glasbey)\n",
    "\n",
    "eval_metrics_text = dict(zip(METRICS.keys(),\n",
    "                             ['Exact accuracy','Partial accuracy','Precision','Recall','F1 Score','Specificity']))\n",
    "\n",
    "n = QUERY_TEST_REINDEXED.loc[within_scope_ind].shape[0]\n",
    "plot_results = {\n",
    "    'RAG + dense-only': {k: v['5']*100 for k, v in all_queries_average['dense'].items()},\n",
    "    'RAG + hybrid': {k: v['5']*100 for k, v in all_queries_average['hybrid'].items()},\n",
    "    f'RAG + hybrid (within scope, {n=})': {k: v['5']*100 for k, v in within_scope_queries_average['hybrid'].items()}\n",
    "}\n",
    "\n",
    "plot_radar_chart(\n",
    "    eval_results=plot_results, \n",
    "    metrics=eval_metrics_text.keys(), \n",
    "    metric_labels=eval_metrics_text,\n",
    "    title=None,\n",
    "    colors=[cols[6],cols[0],cols[1]]\n",
    "    )"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "075964bf",
   "metadata": {},
   "source": [
    "### Inspect success and failed cases in dense-only search vs. hybrid search"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "id": "ce481ad6",
   "metadata": {},
   "outputs": [],
   "source": [
    "QUERY_SCOPE=QUERY_TEST_REINDEXED.loc[within_scope_ind]\n",
    "QUERY_SCOPE.reset_index(inplace=True)\n",
    "QUERY_SCOPE.rename(columns={'level_0':'test_query_index','index':'all_query_index'}, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "id": "c8b52d6c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                                 mean       std\n",
      "Both Success                     56.0  0.707107\n",
      "Dense Success and Hybrid Failed   0.6  0.894427\n",
      "Dense Failed and Hybrid Success   3.0  0.707107\n",
      "Both Failed                      14.4  1.140175\n"
     ]
    }
   ],
   "source": [
    "all_results = []\n",
    "for i in range(5): \n",
    "    dense_partial_failed = ~np.array(evaluator_within_scope_queries.evals['RAG']['dense']['5'][i]['partial_match_acc'])\n",
    "    hybrid_partial_failed = ~np.array(evaluator_within_scope_queries.evals['RAG']['hybrid']['5'][i]['partial_match_acc'])\n",
    "    all_results.append(compare_mode_A_vs_B(dense_partial_failed, hybrid_partial_failed))\n",
    "\n",
    "arr = np.array(all_results)\n",
    "\n",
    "summary = pd.DataFrame({\n",
    "    \"Both Success\": arr[:,0],\n",
    "    \"Dense Success and Hybrid Failed\": arr[:,1],\n",
    "    \"Dense Failed and Hybrid Success\": arr[:,2],\n",
    "    \"Both Failed\": arr[:,3]\n",
    "})\n",
    "\n",
    "summary_stats = summary.agg(['mean', 'std']).T\n",
    "print(summary_stats)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "id": "ea0db235",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 600x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "fig, ax = plt.subplots(figsize=(3, 3), dpi=200)\n",
    "\n",
    "avg_cm = np.array([\n",
    "    [summary_stats.loc[\"Both Success\",\"mean\"], summary_stats.loc[\"Dense Success and Hybrid Failed\",\"mean\"]],\n",
    "    [summary_stats.loc[\"Dense Failed and Hybrid Success\",\"mean\"], summary_stats.loc[\"Both Failed\",\"mean\"]]\n",
    "])\n",
    "sns.heatmap(avg_cm, annot=True, annot_kws={\"fontsize\": 12},\n",
    "            fmt=\".1f\", cmap=\"Purples\", cbar=False,\n",
    "            xticklabels=[\"Hybrid Success\", \"Hybrid Failed\"],\n",
    "            yticklabels=[\"Dense Success\", \"Dense Failed\"])\n",
    "plt.title(\"Dense-only vs. Hybrid\\nacross iterations (mean counts)\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 140,
   "id": "5472760f",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_results_idx = []\n",
    "for i in range(5): \n",
    "    dense_partial_failed = ~np.array(evaluator_within_scope_queries.evals['RAG']['dense']['5'][i]['partial_match_acc'])\n",
    "    hybrid_partial_failed = ~np.array(evaluator_within_scope_queries.evals['RAG']['hybrid']['5'][i]['partial_match_acc'])\n",
    "    all_results_idx.append(compare_mode_A_vs_B_idx(dense_partial_failed, hybrid_partial_failed))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 141,
   "id": "0c337e28",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "count",
         "rawType": "int64",
         "type": "integer"
        }
       ],
       "ref": "382919ef-6241-482a-a78a-e6a3bc0ac364",
       "rows": [
        [
         "11",
         "5"
        ],
        [
         "13",
         "5"
        ],
        [
         "19",
         "5"
        ],
        [
         "23",
         "5"
        ],
        [
         "26",
         "5"
        ],
        [
         "35",
         "5"
        ],
        [
         "37",
         "5"
        ],
        [
         "41",
         "5"
        ],
        [
         "50",
         "5"
        ],
        [
         "52",
         "5"
        ],
        [
         "53",
         "5"
        ],
        [
         "57",
         "5"
        ],
        [
         "61",
         "5"
        ],
        [
         "45",
         "4"
        ],
        [
         "20",
         "2"
        ],
        [
         "54",
         "1"
        ]
       ],
       "shape": {
        "columns": 1,
        "rows": 16
       }
      },
      "text/plain": [
       "11    5\n",
       "13    5\n",
       "19    5\n",
       "23    5\n",
       "26    5\n",
       "35    5\n",
       "37    5\n",
       "41    5\n",
       "50    5\n",
       "52    5\n",
       "53    5\n",
       "57    5\n",
       "61    5\n",
       "45    4\n",
       "20    2\n",
       "54    1\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 141,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_runs=[all_results_idx[i]['both_failed'] for i in range(5)]\n",
    "pd.Series([x for run in all_runs for x in run]).value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 248,
   "id": "c983c732",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "11\n",
      "============= dense =============\n",
      "{frozenset({'pembrolizumab'})}\n",
      "============= hybrid =============\n",
      "set()\n",
      "============= ground-truth =============\n",
      "{frozenset({'cabozantinib', 'nivolumab'}), frozenset({'pembrolizumab', 'lenvatinib'}), frozenset({'ipilimumab', 'nivolumab'}), frozenset({'axitinib', 'avelumab'}), frozenset({'axitinib', 'pembrolizumab'})}\n",
      "13\n",
      "============= dense =============\n",
      "{frozenset({'erdafitinib'})}\n",
      "============= hybrid =============\n",
      "{frozenset({'erdafitinib'})}\n",
      "============= ground-truth =============\n",
      "{frozenset({'enfortumab vedotin'})}\n",
      "19\n",
      "============= dense =============\n",
      "set()\n",
      "============= hybrid =============\n",
      "set()\n",
      "============= ground-truth =============\n",
      "{frozenset({'cabozantinib'})}\n",
      "23\n",
      "============= dense =============\n",
      "set()\n",
      "============= hybrid =============\n",
      "set()\n",
      "============= ground-truth =============\n",
      "{frozenset({'doxorubicin'}), frozenset({'cisplatin'}), frozenset({'methotrexate'})}\n",
      "26\n",
      "============= dense =============\n",
      "{frozenset({'midostaurin', 'cytarabine', 'daunorubicin'})}\n",
      "============= hybrid =============\n",
      "{frozenset({'midostaurin', 'cytarabine', 'daunorubicin'})}\n",
      "============= ground-truth =============\n",
      "{frozenset({'gilteritinib'})}\n",
      "35\n",
      "============= dense =============\n",
      "set()\n",
      "============= hybrid =============\n",
      "set()\n",
      "============= ground-truth =============\n",
      "{frozenset({'talazoparib'})}\n",
      "37\n",
      "============= dense =============\n",
      "set()\n",
      "============= hybrid =============\n",
      "set()\n",
      "============= ground-truth =============\n",
      "{frozenset({'ivosidenib'})}\n",
      "41\n",
      "============= dense =============\n",
      "set()\n",
      "============= hybrid =============\n",
      "set()\n",
      "============= ground-truth =============\n",
      "{frozenset({'ibrutinib'})}\n",
      "50\n",
      "============= dense =============\n",
      "{frozenset({'panitumumab'})}\n",
      "============= hybrid =============\n",
      "{frozenset({'panitumumab'})}\n",
      "============= ground-truth =============\n",
      "{frozenset({'bevacizumab'})}\n",
      "52\n",
      "============= dense =============\n",
      "set()\n",
      "============= hybrid =============\n",
      "set()\n",
      "============= ground-truth =============\n",
      "{frozenset({'encorafenib', 'centuximab'}), frozenset({'bevacizumab'})}\n",
      "53\n",
      "============= dense =============\n",
      "set()\n",
      "============= hybrid =============\n",
      "set()\n",
      "============= ground-truth =============\n",
      "{frozenset({'bevacizumab'})}\n",
      "57\n",
      "============= dense =============\n",
      "set()\n",
      "============= hybrid =============\n",
      "set()\n",
      "============= ground-truth =============\n",
      "{frozenset({'trastuzumab deruxtecan'})}\n",
      "61\n",
      "============= dense =============\n",
      "set()\n",
      "============= hybrid =============\n",
      "set()\n",
      "============= ground-truth =============\n",
      "{frozenset({'trastuzumab', 'tucatinib'})}\n"
     ]
    }
   ],
   "source": [
    "for i in range(5):\n",
    "    idx=all_results_idx[i]['both_failed']\n",
    "    for j in idx:\n",
    "        print(j)\n",
    "        print(\"============= dense =============\")\n",
    "        print(evaluator_within_scope_queries.evals['RAG']['dense']['5'][i]['pred_drugs_generic_set_ls'][j])\n",
    "        print(\"============= hybrid =============\")\n",
    "        print(evaluator_within_scope_queries.evals['RAG']['hybrid']['5'][i]['pred_drugs_generic_set_ls'][j])\n",
    "        print(\"============= ground-truth =============\")\n",
    "        print(evaluator_within_scope_queries.evals['RAG']['dense']['5'][i]['true_drugs_generic_set_ls'][j])\n",
    "    break"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c9509b89",
   "metadata": {},
   "source": [
    "Drug indication not linked to a biomarker: 19, 23 "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 238,
   "id": "81206da6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                                 mean       std\n",
      "Both Success                     43.6  0.547723\n",
      "Dense Success and Hybrid Failed   0.8  0.836660\n",
      "Dense Failed and Hybrid Success   1.8  0.447214\n",
      "Both Failed                      27.8  1.095445\n"
     ]
    }
   ],
   "source": [
    "all_results = []\n",
    "for i in range(5): \n",
    "    dense_exact_failed = ~np.array(evaluator_within_scope_queries.evals['RAG']['dense']['5'][i]['exact_match_acc'])\n",
    "    hybrid_exact_failed = ~np.array(evaluator_within_scope_queries.evals['RAG']['hybrid']['5'][i]['exact_match_acc'])\n",
    "    all_results.append(compare_mode_A_vs_B(dense_exact_failed, hybrid_exact_failed))\n",
    "\n",
    "arr = np.array(all_results)\n",
    "\n",
    "summary = pd.DataFrame({\n",
    "    \"Both Success\": arr[:,0],\n",
    "    \"Dense Success and Hybrid Failed\": arr[:,1],\n",
    "    \"Dense Failed and Hybrid Success\": arr[:,2],\n",
    "    \"Both Failed\": arr[:,3]\n",
    "})\n",
    "\n",
    "summary_stats = summary.agg(['mean', 'std']).T\n",
    "print(summary_stats)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 239,
   "id": "54fd2844",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 600x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "fig, ax = plt.subplots(figsize=(3, 3), dpi=200)\n",
    "\n",
    "avg_cm = np.array([\n",
    "    [summary_stats.loc[\"Both Success\",\"mean\"], summary_stats.loc[\"Dense Success and Hybrid Failed\",\"mean\"]],\n",
    "    [summary_stats.loc[\"Dense Failed and Hybrid Success\",\"mean\"], summary_stats.loc[\"Both Failed\",\"mean\"]]\n",
    "])\n",
    "sns.heatmap(avg_cm, annot=True, annot_kws={\"fontsize\": 12},\n",
    "            fmt=\".1f\", cmap=\"Purples\", cbar=False,\n",
    "            xticklabels=[\"Hybrid Success\", \"Hybrid Failed\"],\n",
    "            yticklabels=[\"Dense Success\", \"Dense Failed\"])\n",
    "plt.title(\"Dense-only vs. Hybrid\\nacross iterations (mean counts)\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9c3445b7",
   "metadata": {},
   "source": [
    "### Edge cases or rare cases analysis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8522ab00",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
